Biosynth, Korea; carbohydrates and nucleosides - 연구용 시약 수입/공급 전문 코아사이언스

안녕하세요!

 

Carbohydrates 및 nucleosides 제조/공급  전문 기업 Biosynth 수입, 공급 업체 코아사이언스입니다.  

견적 및 관련 문의는 FAX 02-6910-0329나 info@coresciences.co.kr로 연락주세요.

감사합니다! 

 

Biosynth's mission is to supply critical raw materials and services to the pharmaceutical, vaccine, and diagnostic industries. Biosynth strives to de-risk its customer's supply chains.

Biosynth's vision is to consolidate the highly fragmented and complex supply chain. Biosynth increases productivity of the pharmaceutical and diagnostics industries by improving availability and reducing time-to-market of new therapies and diagnostics assays. Biosynth is viewed as a strategic partner to many of the leading companies in the market.

Who we are

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals - where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation.  

With an unrivalled research product portfolio of over a million products and end-to-end manufacturing services, we are science led and customer focused to solve problems, taking pride in delivering products and projects that others cannot. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner.

Biosynth is an innovative life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in small molecules, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. 

Our complex chemistry specialties include enzyme substrates, carbohydrate and nucleoside chemistry, with manufacturing services from the first idea to the finished product, from route scouting to GMP or ton scale production. For peptides, we also have a full end-to-end offering, from lead discovery and optimization, library production, through to GMP NCE or Neoantigen projects.  

Across biologics we have a synergistic offering, with an extensive range of custom bioprocessing enzyme projects for production of key products. We are also able to offer custom antibody projects, and epitope mapping. Through the Biosynth group we also offer development of antibodies, antigens and supply of plasma for in vitro diagnostics.  

The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. Our main chemical research and manufacturing laboratories are in Switzerland, the United Kingdom, Slovakia and China, with peptide production in the USA, the Netherlands and UK. Enzyme projects are based in Austria and biological IVD reagents in Ireland.  Our R&D resources and production facilities are modern and versatile, allowing us to produce chemicals on the milligram to multi-ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. 

 

Our History

Biosynth was founded in 1966 by Hans Spitz, and has grown to a global products and services business. Biosynth merged with Carbosynth in 2019 to form Biosynth Carbosynth, creating a world leader in carbohydrates, nucleososides and enzyme substrates. In 2022 Biosynth Group acquired both vivitide and Pepscan, which strengthened the offering in peptide manufacturing services and catalog products. Also in 2022 Biosynth Group acquired Aalto Bio Reagents, expanding the range of biological products and key raw materials for clinical diagnostics including antigens and antibodies, as well as EUCODIS Bioscience, experts in enzyme development. Following these acquisitions, the company returned to the Biosynth brand. In 2023 Biosynth acquired Fitzgerald Industries International and a significant catalog of antibodies and antigens, along with Cambridge Research Biochemicals (CRB), adding further expertise in peptide and antibody production. Also in 2023, Biosynth added bioconjugation services with the acquisition of celares. Biosynth also expanded their GMP peptide manufacturing to multi-kg scale with the addition of Pepceutials to the Group. At the end of 2023, Biosynth expanded the capacity for larger scale chemicals manufacturing with the acquisition of VIO Chemicals.  Biosynth is owned, amongst others, by KKR, Ampersand and senior management.

코아사이언스 coresciences Biosynth Carbosynth Korea 한국 대리점